Distinct tau PET dynamics in early versus late age-of-onset Alzheimer’s disease
- 4 November 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (874)
Abstract
Early-onset Alzheimer’s disease (EOAD) and late-onset AD (LOAD) differ in clinical presentations and rates of progression. We aimed to compare baseline and longitudinal tau positron emission tomography (PET) burden measured with 18 F-flortaucipir and its relationship with clinical variables in amyloid PET–positive, cognitively impaired participants from the Longitudinal Early-Onset Alzheimer’s Disease Study (EOAD; n = 390) and Alzheimer’s Disease Neuroimaging Initiative (LOAD; n = 211). Participants with EOAD showed higher baseline tau PET burden, broader neuroanatomical involvement, and stronger associations of tau PET with amyloid PET and global cognition. Higher baseline tau PET burden in EOAD was independently validated in participants with EOAD from ADNI. Longitudinally, tau PET increased more rapidly in EOAD than in LOAD, independent of amyloid PET and clinical stage. We conclude that earlier age of onset in AD is linked to a more aggressive tauopathy, which in turn is a primary driver of clinical decline.Keywords
Funding Information
- National Institutes of Health (R01-NS139383)
- National Institute on Aging (U19AG024904)
- National Institute on Aging (R56-AG057195)
- National Institute on Aging (P30-AG062422)
- National Institute on Aging (R35-AG072362)
- National Institute on Aging (U01-AG082350)
- National Institute on Aging (R56-AG075744)
- National Institute on Aging (U19-AG024904)
- Alzheimer's Association (AARG-22-926940)
- Alzheimer's Association (LDRFP-21-818464)
- Alzheimer's Association (LEADS GENETICS-19-639372)
- Alzheimer's Association (ZEN-21-848216)
- American College of Radiology
- Rainwater Charitable Foundation
- Alliance for Therapies in Neuroscience
This publication has 54 references indexed in Scilit:
- Evaluation of Copathology and Clinical Trajectories in Individuals With Tau-Clinical MismatchJAMA Neurology, 2026
- Estimated Age of Amyloid Onset in Participants with Early‐ versus Late‐Onset Alzheimer’s Disease: Results from the LEADS & ADNI StudiesAlzheimer's & Dementia, 2023
- ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid LevelsJAMA Neurology, 2023
- Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer DiseaseJAMA Neurology, 2023
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- White matter hyperintensities are higher among early‐onset Alzheimer's disease participants than their cognitively normal and early‐onset nonAD peers: Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)Alzheimer's & Dementia, 2023
- Early‐onset Alzheimer's disease shows a distinct neuropsychological profile and more aggressive trajectories of cognitive decline than late‐onsetAnnals of Clinical and Translational Neurology, 2022
- Rates of longitudinal change in 18F‐flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's diseaseAlzheimer's & Dementia, 2021
- The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodologyAlzheimer's & Dementia, 2021
- Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic ChangesJAMA Neurology, 2020